肺癌恶性胸水患者重组人血管内皮抑素联合顺铂方案胸腔化疗后胸水肿瘤标志物变化与疗效的相关性.docVIP

精品论文 参考文献 肺癌恶性胸水患者重组人血管内皮抑素联合顺铂方案胸腔化疗后胸水肿瘤标志物变化与疗效的相关性 韩云 迪吉(通讯作者) 杨生虎 　　（青海大学附属医院 青海西宁 810001) 　　【摘要】目的 观察肺癌恶性胸水患者在重组人血管内皮抑素联合顺铂方案胸腔化疗后胸水肿瘤标志物的变化。方法 分析接受管内皮抑素联合顺铂胸腔化疗的肺癌患者36例, 观察治疗前后肿瘤标志物CEA、TPS及CYFRA21-1的变化,并根据治疗前后影像学结果的改变来进行对比。结果 治疗后CEA、TPS及CYFRA21-1均值与化疗前都有不同程度下降, 其中CEA下降44.3% (P＜0.05)，TPS下降53.32% (P＜0.05),CYFRA21-1下降32.15% (P＜0.05)。患者肿瘤标志物疗效与临床疗效的相关性分析结果表明, CEA、TPS、CYFRA21-1的疗效与临床疗效呈正相关。三者联合检测与临床疗效呈正相关。结论 肺癌恶性胸水患者肿瘤标志物CEA、CA125、CYFRA21-1水平的改变是反映血管内皮抑素疗效的可靠指标, 通过监测患者胸水肿瘤标志物水平的改变可以协助判断治疗疗后疗效。 　　【关键词】 恶性胸水 血管内皮抑素/顺铂 肿瘤标志物 　　【中图分类号】R563 【文献标识码】A 【文章编号】2095-1752（2014）06-0096-02 　　 　　【Abstract】Objective Observe lung cancer patients with malignant pleural effusion in rh-endostation cisplatin chemotherapy scheme after malignant pleural effusion tumor markers of change. Methods Analysis accept rh-endostation cisplatin chemotherapy patients with lung cancer of the malignant pleural effusion 36 cases, observed before and after treatment of tumor marker CEA, TPS and CYFRA21-1 changes, and according to the results of the imaging before and after treatment to change to are compared. Results After chemotherapy, tumor markers like CEA, TPS and CYFRA21-1were decreased, in which CEA, TPS and CYFRA21-1 diminished 44.3% (P＜0.05), 53.32% (P＜0.05), and32.15% (P＜0.05).CEA, TPS, CYFRA 21-1 the curative effect and the clinical curative effect were positively correlated. The three joint test was positively associated with the clinical effect. Conclusion Chest water CEA, CA125 and CYFRA21-1 represent reliable markers for chemotherapy efficacy on patients with lung cancer. Monitoring changes of serum levels of tumor markers would benefit for assessment of chemotherapy efficacy 　　【Key words】Malignant pleural effusion rh-endostation/ cisplatin tumor markers 　　恶性胸水是晚期肺癌的常见并发症，此类患者不宜手术亦无放疗指征。从诊断到死亡平均约3个月[1]。目前临床多采用胸腔灌注化疗、手术、免疫及热疗的综合治疗模式，但总体疗效有限。分子靶向药物血管内皮抑素（恩度）抑制肿瘤新生血管形成，毒性低且不易产生耐药。已广泛应用于恶性胸水的治疗中[2][3]。目前分子靶向药物治疗恶